Literature DB >> 27399311

Increased survival and decreased recurrence in colorectal cancer patients diagnosed in a screening programme.

Mónica Mengual-Ballester1, Enrique Pellicer-Franco2, Graciela Valero-Navarro2, Victoriano Soria-Aledo2, José Andrés García-Marín2, José Luis Aguayo-Albasini3.   

Abstract

INTRODUCTION: Population-based screening programmes for colorectal cancer (CRC) allow an early diagnosis, even before the onset of symptoms, but there are few studies and none in Spain on the influence they have on patient survival. The aim of the present study is to show that patients receiving surgery for CRC following diagnosis via a screening programme have a higher survival and disease-free survival rate than those diagnosed in the symptomatic stage.
MATERIAL AND METHODS: Prospective study of all the patients undergoing programmed surgery for CRC at the JM Morales Meseguer Hospital in Murcia (Spain) between 2004 and 2010. The patients were divided into two groups: (a) those diagnosed through screening (125 cases); and (b) those diagnosed in the symptomatic stage (565 cases). Survival and disease-free survival were analysed and compared for both groups using the Mantel method.
RESULTS: The screen-detected CRC patients show a higher rate of survival (86.3% versus 72.1% at 5 years, p<0.05) and a lower rate of tumour recurrence (73.4% versus 88.3% at 5 years, p<0.05).
CONCLUSIONS: Population-based screening for CRC is an effective strategic measure for reducing mortality specific to this neoplasia.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Cancer screening; Colorectal cancer; Colorectal cancer recurrence; Colorectal cancer screening; Colorectal cancer survival

Mesh:

Year:  2016        PMID: 27399311     DOI: 10.1016/j.canep.2016.06.003

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  4 in total

1.  Postoperative Outcomes of Screen-Detected vs Non-Screen-Detected Colorectal Cancer in the Netherlands.

Authors:  Michael P M de Neree Tot Babberich; Nina C A Vermeer; Michel W J M Wouters; Wilhelmina M U van Grevenstein; Koen C M J Peeters; Evelien Dekker; Pieter J Tanis
Journal:  JAMA Surg       Date:  2018-12-19       Impact factor: 14.766

2.  Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer.

Authors:  Xiaobing Wang; Zhaogang Yang; Haimei Tian; Yanfen Li; Mo Li; Wenya Zhao; Chao Zhang; Teng Wang; Jing Liu; Aili Zhang; Di Shen; Cuining Zheng; Jun Qi; Dan Zhao; Junfeng Shi; Liliang Jin; Jianyu Rao; Wei Zhang
Journal:  Oncotarget       Date:  2017-04-11

Review 3.  Heparan Sulfate Proteoglycans in Human Colorectal Cancer.

Authors:  Carolina Meloni Vicente; Daiana Aparecida da Silva; Priscila Veronica Sartorio; Tiago Donizetti Silva; Sarhan Sydney Saad; Helena Bonciani Nader; Nora Manoukian Forones; Leny Toma
Journal:  Anal Cell Pathol (Amst)       Date:  2018-06-20       Impact factor: 2.916

Review 4.  Mouse models of colorectal cancer: Past, present and future perspectives.

Authors:  Florian Bürtin; Christina S Mullins; Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2020-04-07       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.